A path Syntekabio has followed.

  • 2017

    06. kFDA WS GMP Certification

    05. HLAtyping Clinical Validation
    (BMC Bioinformatics, 2017)

    02. Inha University Hospital Precision Medicine Inititive MOU

  • 2016

    10. Chronic Disease Management joint research MOU with ‘Huray Positive’

    10. Strategic business alliance MOU with ‘Oracle Medical’

    09. Parkinson Disease new drug joint research MOU with ‘Kainosmed’

    08. Strategic collaboration3 partnership MOU with ‘Toolgen’

    06. Obtained ‘New Excellent Technology’ related to genetic disease screening

    01. Registered as genetic testing agency of Korea Centers for Disease Control and Prevention

  • 2015

    11. Introduction of Dx NGS equipment permitted by Ministry of food and drug

    09. Colorectal cancer/ breast cancer market technology transfer with KIST theragnosis research team

    08. Established Seoul Business Center and Cheongju Supercom Center

    08. Moved to head office to Daejeon Migeon Techno World II

    02. PMAP (Personal Genomic Map) Automatically Generated Beta Version Completed

  • 2014

    03. Konkuk University Hospital & Konkuk Medical Graduate School BK21 Business team MOU

    04. Selected as Research Instutute by Electronics and Telecommunications Research Institute (ETRI)

  • 2013

    12. Selected as “2020 Future 100 Technology and leaders”

    04. RVR DBMS / Search System US Patent Office Registration Decision

    04. Technology/ sales cooperation MOU with SLS medical diagnostic testingcompany.

  • 2012

    02. Completion of Genome Analysis Platform (NGS-pL)

    01. Integrated genome integration service of next-generation personalized medical genome project team’

  • 2011

    08. Next-Generation Personalized Medical Genome Project Consolidation Service

    04. Established research center (Post-OMICS)

  • 2010

    07. Establizhed business headquarter at Silicon Valley, CA, USA.

    06. Moved to Korea Institute of Science and Technology venture center

  • 2009

    12. Technology Guarantee Fund Venture Certification

    10. Changed company name and CEO: Syntekabio Inc.

    08. Established. Yoobiori

Jongsun Jung

Jongsun Jung

American University Ph.D.

Centers for Disease Control and Prevention, NIH in US

R&D representative CTO
(Daejeon Genome Data Integration Center)

Tyson Kim

Tyson Kim

Doctoral Course at Seoul National University School of Medicine

MSD(Merck & Co.)

President in Business Department
(Gwanghwamun Business center)

Yangrae Cho

Yangrae Cho
Genomic Interpretation R&D Director

Indiana University Ph.D.

Stanford University, biotechnology researcher

Analysis of Personal Genome Map
(Daejeon Genome Data Integration Center)

Jae-Yeon Yoo

Jae-Yeon Yoo
Genomic Visualization R&D Director

Pohang University of Science and Technology, Ph.D.

Researcher at electronics and telecommunications research institute

Personalized Genome Map Visualization
(Daejeon Genome Data Integration Center)

Jae-Min Shin

Jae-Min Shin
In Silico R&D Director


Molecular design research center, NIH in US

in silico medical research
(Yongin in silico medical research center)

Maeng, Jae Yeourl

Maeng, Jae Yeourl
Sales & BD Director

Aalto EMBA

UCB Korea,
Merck & Co.

Sales general director
(Gwanghwamun Business center)